{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'There are two courses. The first treatment course includes 5 consecutive days of infusion, and the', 'second treatment course is administered 12 months after the first treatment course and includes 3', 'consecutive days of infusion. The numbers and percentages of patients that received each possible', 'level of total dose will be presented in the clinical study report.', '11.4.2 Analyses of efficacy endpoints', 'Analyses for the primary and secondary efficacy endpoints will be conducted using the mITT', 'population.', '11.4.2.1 Analysis of primary efficacy endpoint', 'The number of new or enlarging T2 lesions during continuation of prior DMT (Period 1) and in an', 'equal-length period after the first course of alemtuzumab treatment (Period 2) will be analyzed', 'and compared using a repeated measures negative binomial regression model with GEE. The', 'default log link function will be used to model the expected number of lesions. The robust,', 'sandwich covariance matrix will be constructed assuming an unstructured/exchangeable working', 'correlation matrix.', 'The primary statistical objective is to test superiority of alemtuzumab versus prior DMT at 5%', 'level of significance. No missing data is expected as the mITT population is restricted to the', 'patients with evaluable data for both Period 1 and Period 2.', '11.4.2.2 Analyses of secondary efficacy endpoints', 'The annualized relapse rate at Year 2 will be estimated using a negative binomial model with', 'robust variance estimation.', 'The EDSS, descriptive statistics, (eg, percentages of stable/improved/worsened since the end of', 'Period 1) will be calculated.', 'Descriptive statistics (eg, mean, median, min, max, SD, quartiles) and 95% confidence interval for', 'the means, when appropriate, will be calculated for the change from baseline in cognitive', 'outcomes and QoL measures at each prescheduled, postbaseline assessment visit.', 'The proportion of patients with new or enlarging T2 lesions during Period 1 and Period 2 will be', 'analyzed and compared using repeated measures logistic regression model with GEE and robust', 'variance estimation. The analyses will be similar to the primary endpoint analyses with the', 'exception of the use of the logit link function and the Bernoulli distribution.', '11.4.2.3 Multiplicity considerations', 'There is no formal hypothesis testing for the secondary efficacy endpoints, therefore the study', 'overall type I error will not need to be adjusted for multiplicity.', 'Property of the Sanofi Group - strictly confidential', 'Page 86', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '11.4.3 Analyses of safety data', '11.4.3.1 Adverse events', 'AE observation period:', 'Pretreatment AEs are defined as those AEs that developed or worsened prior to the 1st', 'alemtuzumab dose.', 'On treatment AEs are defined as those AEs that developed or worsened after the 1st', 'alemtuzumab dose and until the end of the study (Month 60).', 'Posttreatment AEs are defined as those AEs that developed or worsened after the', 'ontreatment period.', 'On-study period will include pretreatment and ontreatment period. Treatment emergent adverse', 'events (TEAEs) for analysis purpose will include all ontreatment AEs.', 'The primary analysis of adverse event reporting will be on TEAEs. Pretreatment AEs will be', 'summarized separately.', 'The incidence of TEAEs (including IARs), AESI, will also be tabulated (frequencies and', 'percentages) by severity, grade/intensity, and relationship to study drug. In tabulating severity of', 'AEs on a per patient basis, the greatest severity will be assigned to a patient when there is more', 'than one occurrence of the same AE with different reported severities. Relationships of the AE to', 'treatment will be categorized as not related, or related. The highest level of association will be', 'reported in patients with differing relationships for the same AE. Actions taken regarding', 'treatment and patient outcome will also be listed.', 'In addition to IARs analysis above, TEAEs that occurs from start of infusion up to 72 hours', 'postinfusion will be summarized if applicable.', 'The incidence of AEs leading to study discontinuations will also be summarized by treatment', 'group, with details provided in the listing.', 'Death: The following deaths summaries will be generated:', 'Number (%) of patients who died by study period (TEAE, on-study) and reasons for death', 'summarized on the safety population.', 'TEAE leading to death (death as an outcome on the AE e-CRF page as reported by the', 'Investigator) by primary system organ class (SOC), high level group term (HLGT), high', 'level term (HLT) and preferred term (PT) showing number (%) of patients sorted by', 'internationally agreed order of SOC and alphabetic order of HLGT, HLT, and PT.', '11.4.3.2 Laboratory safety variables', 'Observed measurements and changes from baseline to scheduled study visits in biochemistry,', 'hematology, and urinalysis will be descriptively summarized. All laboratory values will be', 'Property of the Sanofi Group - strictly confidential', 'Page 87', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}